Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Protagonist Therapeutics (PTGX) Long-Term Debt Issuances (2019 - 2023)

Protagonist Therapeutics' Long-Term Debt Issuances history spans 4 years, with the latest figure at $24.3 million for Q1 2023.

  • For Q1 2023, Long-Term Debt Issuances rose 66.99% year-over-year to $24.3 million; the TTM value through Dec 2023 reached $24.3 million, up 66.99%, while the annual FY2023 figure was $24.3 million, 66.99% up from the prior year.
  • Long-Term Debt Issuances for Q1 2023 was $24.3 million at Protagonist Therapeutics, up from $14.6 million in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $34.0 million in Q3 2019 and bottomed at -$24.7 million in Q4 2019.
  • The 4-year median for Long-Term Debt Issuances is $16.7 million (2020), against an average of $12.2 million.
  • The largest YoY upside for Long-Term Debt Issuances was 176.2% in 2020 against a maximum downside of 81.23% in 2020.
  • A 4-year view of Long-Term Debt Issuances shows it stood at -$24.7 million in 2019, then soared by 176.2% to $18.8 million in 2020, then dropped by 22.77% to $14.6 million in 2022, then soared by 66.99% to $24.3 million in 2023.
  • Per Business Quant, the three most recent readings for PTGX's Long-Term Debt Issuances are $24.3 million (Q1 2023), $14.6 million (Q1 2022), and $18.8 million (Q4 2020).